[1]张继珂,王振雷.帕瑞昔布对肝癌细胞凋亡及增殖的影响[J].新乡医学院学报,2020,37(8):713-719.[doi:10.7683/xxyxyxb.2020.08.003]
　ZHANG Jike,WANG Zhenlei.Effect of parecoxib on apoptosis and proliferation of hepatocellular cancer cells[J].Journal of Xinxiang Medical University,2020,37(8):713-719.[doi:10.7683/xxyxyxb.2020.08.003]
点击复制

帕瑞昔布对肝癌细胞凋亡及增殖的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年8
页码:
713-719
栏目:
基础研究
出版日期:
2020-08-05

文章信息/Info

Title:
Effect of parecoxib on apoptosis and proliferation of hepatocellular cancer cells
作者:
张继珂1;  王振雷2
(1.郑州市第三人民医院麻醉科,河南　郑州　450000；2.河南省肿瘤医院普外科,河南　郑州　450008)
Author(s):
ZHANG Jike1; WANG Zhenlei2
(1.Department of Anesthesia,the Third People′s Hospital of Zhengzhou,Zhengzhou 450000,Henan Province,China;2.Department of General Surgery,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China)
关键词:
帕瑞昔布; 肝癌; 细胞增殖; 细胞凋亡
Keywords:
parecoxib; hepatocellular cancer; cell proliferation; cell apoptosis
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2020.08.003
文献标志码:
A
摘要:
目的　评价帕瑞昔布对肝癌细胞系HepG2和QGY-7703增殖及凋亡的影响。 方法　取对数生长期HepG2和QGY-7703细胞，消化后制成单细胞悬液接种于6孔板，将细胞分为对照组和10、20、30、40、50 mg·L-1帕瑞昔布处理组。对照组细胞用正常培养基培养，帕瑞昔布处理组细胞分别用含有10、20、30、40、50 mg·L-1帕瑞昔布的培养基培养24 h。采用Annexin V标记法检测各组细胞凋亡情况，5-乙炔基-2′脱氧尿嘧啶核苷嵌入法检测各组细胞增殖效率，流式细胞仪检测对照组和20 mg·L-1帕瑞昔布处理组细胞周期分布，免疫印迹法检测各组细胞中c-myc、cyclin D1、mcl-1蛋白表达。结果　不同浓度帕瑞昔布处理组HepG2细胞凋亡率均显著高于对照组（P<0.05），不同浓度帕瑞昔布处理组HepG2细胞凋亡率随帕瑞昔布浓度的增加而升高（P<0.05）。10 mg·L-1帕瑞昔布处理组QGY-7703细胞凋亡率与对照组比较差异无统计学意义（P>0.05），20、30、40、50 mg·L-1帕瑞昔布处理组QGY-7703细胞凋亡率均显著高于10 mg·L-1帕瑞昔布处理组和对照组（P<0.05）；20、30、40、50 mg·L-1帕瑞昔布处理组QGY-7703细胞凋亡率比较差异均无统计学意义（P>0.05）。与对照组比较，不同浓度帕瑞昔布处理组HepG2细胞增殖率均降低，且随帕瑞昔布浓度的增加呈下降趋势，QGY-7703细胞增殖率无明显变化。20 mg·L-1帕瑞昔布处理组HepG细胞处于S期的比例显著低于对照组（P<0.05）； 20 mg·L-1帕瑞昔布处理组和对照组QGY-7703细胞处于S期的比例比较差异无统计学意义（P>0.05）。不同浓度帕瑞昔布处理组HepG2细胞中c-myc、cyclin D1和mcl-1蛋白表达随帕瑞昔布浓度的升高呈下降趋势。各组QGY-7703细胞中c-myc、cyclin D1、mcl-1蛋白表达水平无明显变化。结论　帕瑞昔布可以通过不同机制调控肝癌细胞系HepG2和QGY-7703的存活，其可通过下调c-myc、cyclin D1和mcl-1蛋白表达促进HepG2细胞凋亡并抑制增殖，可通过下调mcl-1蛋白表达水平促进QGY-7703细胞凋亡。2种细胞中只有HepG2呈现出药物剂量依赖性，且HepG2细胞较QGY-7703细胞对帕瑞昔布更为敏感。
Abstract:
Objective　To evaluate the effect of parecoxib on proliferation and apoptosis of hepatocellular cancer cells HepG2 and QGY-7703.Methods　HepG2 and QGY-7703 cells in logarithmic growth phase were taken and digested into single cell suspension and then were inoculated into 6-well plate.Both the HepG2 and QGY-7703 cells were divided into control group and 10,20,30,40,50 mg·L-1 parecoxib treatment group.The cells in control group were cultured in normal medium and the cells in parecoxib treatment group were cultured in medium with 10,20,30,40,50 mg·L-1 parecoxib for 24 h respectively.The cell apoptosis was detected by annexin V labeling method,the proliferation efficiency was detected by 5-ethynyl-29-deoxyuridine embedding method,the cell cycle distribution of the two kinds of cells in the control group and 20 mg·L-1 parecoxib treatment group was detected by flow cytometry and the expression of c-myc,cyclin D1,mcl-1 protein was detected by Western blot.Results　The apoptosis rate of HepG2 cells in different concentrations of parecoxib treatment groups was higher than that in the control group (P<0.05),and the apoptosis rate of HepG2 cells increased with the increase of the concentration of parecoxib (P<0.05).There was no significant difference in the apoptosis rate of QGY-7703 cells between 10 mg·L-1 parecoxib treatment group and the control group (P>0.05);the apoptosis rate of QGY-7703 cells in the 20,30,40,50 mg·L-1 parecoxib treatment group was higher than that in the 10 mg·L-1 parecoxib treatment group and the control group(P<0.05);there was no significant difference in the apoptosis rate of QGY-7703 cells among the 20,30,40 and 50 mg·L-1 parecoxib treatment group (P>0.05).Compared with the control group,the proliferation rate of HepG2 cells in different concentrations of parecoxib group decreased and the proliferation rate decreased with the increase of the concentration of parecoxib;while the proliferation rate of QGY-7703 cells did not change significantly.The percentage of HepG cells in S phase in the 20 mg·L-1 parecoxib treatment group was lower than that in the control group (P<0.05);there was no significant difference in the percentage of QGY-7703 cells in S phase between the 20 mg·L-1 parecoxib treatment group and the control group (P>0.05).The expressions of c-myc，cyclin D1，mcl-1 protein in HepG2 cells in different concentration of parecoxib treatment groups decreased with increase of parecoxib.The expressions of c-myc，cyclin D1，mcl-1 protein in QGY-7703 cells had no significant change in each group.Conclusion　Parecoxib can regulate the survival of HepG2 and QGY-7703 cells through different mechanisms.Parecoxib can promote apoptosis and inhibit proliferation of HepG2 cells by down regulating the expression of c-myc,cyclin D1 and mcl-1 protein；and parecoxib can promote the apoptosis of QGY-7703 cells by down regulating the expression of mcl-1 protein.Only HepG2 cells show a dose-dependent manner,and the HepG2 cells were more sensitive to parecoxib than QGY-7703 cells.

参考文献/References:

［1］　TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012［J］.CA Cancer J Clin,2015,65(2):87-108.
［2］　KANTARJIAN H M,SHAH N P,CORTES J E,et al.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:2-year follow-up from a randomized phase 3 trial (DASISION)［J］.Blood,2012,119(5):1123-1129.
［3］　KORMAN A J,PEGGS K S,ALLISON J P.Checkpoint blockade in cancer immunotherapy［J］.Adv Immunol,2006,90:297-339.
［4］　BALACHANDRAN V P,LUKSZA M,ZHAO J N,et al.Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer［J］.Nature,2017,551(7681):512-516.
［5］　SAHIN U,DERHOVANESSIAN E,MILLER M,et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer［J］.Nature,2017,547(7662):222-226.
［6］　PROMMER E E.Pharmacological management of cancer-related pain［J］.Cancer Control,2015,22(4):412-425.
［7］　庞倩芸，陈博，邓小园，等.术后不同镇痛药对结直肠癌患者预后的影响［J］.中国肿瘤临床，2016，43（14）：635-638.
［8］　梅雷.右美托咪定、帕瑞昔布钠单独或复合用药改善开胸术患者苏醒期躁动的效果及安全性［J］.新乡医学院学报，2018,35（1）：76-79,82.
［9］　赵一璠，马丽，郝建华，等.帕瑞昔布钠应用于重症肌无力胸腺切除术后镇痛的效果［J］.新乡医学院学报，2014,31（5）：364-367.
［10］　方馥肖，马海青，戴树龙.帕瑞昔布对结直肠癌根治术患者中性粒细胞与淋巴细胞比值的影响［J］.全科医学临床与教育，2019,17（7）：633-634.
［11］　HUSSAIN M,JAVEED A,ASHRAF M,et al.Non-steroidal antiinflammatory drugs,tumour immunity and immunotherapy［J］.Pharmacol Res,2012,66(1):7-18.
［12］　SCHACK A,FRANSGAARD T,KLEIN M F,et al.Perioperative use of nonsteroidal anti-inflammatory drugs decreases the risk of recurrence of cancer after colorectal resection:a cohort study based on prospective data［J］.Ann Surg Oncol,2019,26(12):3826-3837.
［13］　LONNROTH C,ANDERSSON M,ARVIDSSON A,et al.Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer［J］.Cancer Immun,2008,8:5.
［14］　SHAO S,DUAN W,XU Q,et al.Curcumin suppresses hepatic stellate cell-induced hepatocarcinoma angiogenesis and invasion through downregulating CTGF［J］.Oxid Med Cell Longev,2019,2019:8148510.
［15］　CHINNAPAKA S,ZHENG G,CHEN A,et al.Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells via hydrogen peroxide (H2O2)-mediated oxidative stress［J］.Free Radic Biol Med,2019,143:494-509.
［16］　龙海涛，李康华，朱勇，等.非甾体类抗炎药对骨肉瘤细胞株增殖和凋亡的影响［J］.中国骨与关节杂志，2012,1（2）：136-140.
［17］　李鹏， 刘江伟，许永华，等.帕瑞昔布对人胰腺癌细胞株BxPC-3、AsPC-1增殖凋亡的影响及其机制［J］.世界华人消化杂志，2012,20（8）：675-679.
［18］　朱宇麟，张晓琪，李锋，等.帕瑞昔布钠对肝癌3 B细胞增殖、凋亡、侵袭迁移的影响［C］.中国医师协会麻醉学医师分会,2016：417-418.
［19］　梁桦，杨承详，王汉兵，等.不同浓度帕瑞昔布对结肠癌LoVo细胞增殖及凋亡的影响［J］.中华麻醉学杂志，2013,32（8）：947-949.

相似文献/References:

[1]王克霞,张荣波,唐小龙,等.肝细胞性肝癌与乙型肝炎病毒感染相关性的研究[J].新乡医学院学报,1997,14(03):281.
[2]杨瑞民,张凯,李玉侠,等.巨块型肝癌肝动脉栓塞后无水酒精注射疗效观察[J].新乡医学院学报,1997,14(04):382.
[3]甄艳华,杨利霞.肝癌患者肝动脉血流动力学的彩色多普勒研究[J].新乡医学院学报,2008,25(01):062.
[4]沈洁,阮健,郑航,等.ZD6474对肝癌HepG2细胞的抑制作用[J].新乡医学院学报,2010,27(03):234.
[5]黄长山,余伟,王云检,等.外科Apgar评分在肝癌术后并发症预测中的应用 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):365.
[6]孙春伟,吴广银.哺乳动物雷帕霉素靶蛋白对肝癌细胞系Hep3B中侧群细胞的影响[J].新乡医学院学报,2011,28(03):307.
[7]王　雷１,王煜霞２,薛会朝１. 肝癌患者肿瘤坏死因子α和白细胞介素８水平变化及其与临床病理特征的关系[J].新乡医学院学报,2015,32(08):735.
[8]罗羽田,李世朋,徐红伟,等.铁死亡在肝癌中的调控机制及作用研究进展[J].新乡医学院学报,2021,38(1):091.[doi:10.7683/xxyxyxb.2021.01.020]
[9]王政强,韩锋博.肝癌切除术联合肝动脉化疗栓塞术治疗中晚期肝癌疗效观察[J].新乡医学院学报,2021,38(10):957.[doi:10.7683/xxyxyxb.2021.10.012]
　WANG Zhengqiang,HAN Fengbo.Effect of hepatectomy combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced liver cancer[J].Journal of Xinxiang Medical University,2021,38(8):957.[doi:10.7683/xxyxyxb.2021.10.012]
[10]李　妍,朱绍辉,张　彬.肝癌患者肝切除术后感染性并发症的相关危险因素分析[J].新乡医学院学报,2016,33(9):767.[doi:10.7683/xxyxyxb.2016.09.007]
　LI Yan,ZHU Shao-hui,ZHANG Bin.Analysis of the risk factors for infectious complications in patients with hepatocellular carcinoma after hepatectomy[J].Journal of Xinxiang Medical University,2016,33(8):767.[doi:10.7683/xxyxyxb.2016.09.007]

更新日期/Last Update: 2020-08-05